UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 3, 2016
Catabasis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
| 001-37467 |
| 26-3687168 |
(State or Other Jurisdiction |
| (Commission |
| (IRS Employer |
One Kendall Square |
| 02139 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (617) 349-1971
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On November 3, 2016, Catabasis Pharmaceuticals, Inc. (the “Company”) and DWF IV One Kendall, LLC (“Divco”) entered into an amendment (the “Amendment”) to the Lease Agreement, dated December 17, 2010, by and between Divco and the Company, as amended (the “Lease”), under which the Company leases approximately 18,876 rentable square feet in a building located at One Kendall Square, Cambridge, Massachusetts, which serves as the Company’s corporate headquarters.
The Amendment extends the expiration date of the Lease term from June 30, 2017 to June 30, 2018. Under the Amendment, the Company is obligated to pay Divco a monthly base rent of $113,256 beginning on March 1, 2017.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the text of the Amendment, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CATABASIS PHARMACEUTICALS, INC. | |
|
|
|
Date: November 7, 2016 | By: | /s/ Jill C. Milne |
|
|
|
|
| Jill C. Milne |
|
| President and Chief Executive Officer |